Analysts have been eager to weigh in on the Conglomerates sector with new ratings on Aptiv (APTV – Research Report) and Core Laboratories (CLB – Research Report). Aptiv (APTV) Barclays analyst Brian Johnson maintained a Buy rating on Aptiv yesterday and set a price target of $186.00. The company's shares closed last Monday at $160.15, close to its 52-week high of $170.47. According to TipRanks.com, Johnson has 0 stars on 0-5 stars ranking scale with an average return of -4.4% and a 48.8% success rate. Johnson covers the Industrial Goods sector, focusing on stocks such as Magna International, Hyliion Holdings, and Otis Worldwide. Currently, the analyst consensus on Aptiv is a Moderate Buy with an average price target of $167.90, implying a 1.8% upside from current levels. In a report issued on September 26, Goldman Sachs also maintained a Buy rating on the stock with a $174.00 price target. See today’s analyst top recommended stocks >> Core Laboratories (CLB) Morgan Stanley analyst Connor Lynagh maintained a Hold rating on Core Laboratories yesterday and set a price target of $34.00. The company's shares closed last Monday at $29.87. According to TipRanks.com, Lynagh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.0% and a 52.2% success rate. Lynagh covers the Industrial Goods sector, focusing on stocks such as Liberty Oilfield Services, Baker Hughes Company, and Helmerich & Payne. Currently, the analyst consensus on Core Laboratories is a Hold with an average price target of $24.83. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on APTV: Analysts Conflicted on These Financial Names: Landmark Infrastructure (LMRK), Essex Property (ESS) and AvalonBay (AVB) Analysts Offer Insights on Materials Companies: Albemarle (ALB) and Cemex SAB (CX) Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Merck & Company (MRK) and Protagonist Therapeutics (PTGX) Interfor (IFSPF) Received its Third Buy in a Row MTY Food Group (MTYFF) Receives a Hold from Scotiabank